AR058403A1 - PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. - Google Patents

PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF.

Info

Publication number
AR058403A1
AR058403A1 ARP060105791A ARP060105791A AR058403A1 AR 058403 A1 AR058403 A1 AR 058403A1 AR P060105791 A ARP060105791 A AR P060105791A AR P060105791 A ARP060105791 A AR P060105791A AR 058403 A1 AR058403 A1 AR 058403A1
Authority
AR
Argentina
Prior art keywords
group
cycloalkyl
arylalkyl
heterocycloalkyl
optionally substituted
Prior art date
Application number
ARP060105791A
Other languages
English (en)
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of AR058403A1 publication Critical patent/AR058403A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Compuestos como inhibidores de proteína quinasas incluyendo B-Raf y diverso receptor de tirosina y tirosina citoplasmática quinasa. Derivados de pirimidiniloxi y piridiniloxi urea sustituida de formulas (1), (2) y (3), y composiciones y sus aplicaciones como fármacos para el tratamiento de enfermedades. Su uso en la preparacion de medicamentos para la modulacion de la actividad de proteína quinasas en un sujeto humano o animal para el tratamiento de enfermedades como el cáncer. Reivindicacion (1): Un compuesto caracterizado porque tiene una formula estructural (4), o una sal, éster o prodroga de lo mismo, en lo cual X1-X4 son seleccionados cada uno independientemente de un grupo formado por C(R2) y N; X5 es seleccionado de un grupo formado por C(R3)(R4), N(R3), O y S(O)m; m es 0, 1 o 2; A y C son seleccionados cada uno en forma independiente de un grupo formado por arilo y heteroarilo, cada uno de los cuales puede ser opcionalmente sustituido; B es seleccionado del grupo formado por -N(R8)C(O)N(R8)- y -N(R8)C(O)N(R8)CH2-; R1 es seleccionado de un grupo formado por heteroarilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido y un resto de formula (5); I, J, K, L y M son seleccionados cada uno en forma independiente de un grupo formado por C(R5)(R6), S(O)n, O y N(R7); n es 0, 1 o 2; R2 es seleccionado de un grupo formado por alquenilo, alcoxi, alcoxialquilo, alquilo, alquinilo, amido, amino, aminoalquilo, ciano, cianoalquenilo, éster, éter, halo, haloalquilo, haloalcoxi, hidrogeno, hidroxido, hidroxialquilo y nitro, cada uno de los cuales puede ser opcionalmente sustituido; R3 y R4 son seleccionados cada uno independientemente del grupo formado por hidrogeno y alquilo inferior; R5 y R6 son seleccionados en forma independiente del grupo formado por alquenilo, alcoxi, alcoxialquilo, alquilo, alquinilo, amido, amidoalquilo, amino, aminoalquilo, aminoalquilamino, arilo, arilalquenilo, arilalquilo, arilalquinilo, ciano, cianoalquilo, cianoalquenilo, cicloalquilo, éster, ésteralquilo, halo, haloalquilo, haloalcoxi, heteroarilo, heteroarilalquenilo, heteroarilalquilo, heterocicloalquenilo, heterocicloalquilo, heterocicloalquilalquilo, heterocicloalquilalcoxi, heterocicloalquilalquiltio, hidrogeno, hidroxi, hidroxialquilo, nitro y nulo cualquiera de los cuales puede ser opcionalmente sustituido; R7 es seleccionado de un grupo formado por alquenilo, alcoxialquilo, alcoxicarbonilo, alquilo, alquilamino, alquileno, alquinilo, amidoalquilo, arilo, arilalcoxi, arilalquilo, arilalquenilo, arilalquinilo, arilcarbonilo, arilsulfonilo, cianoalquenilo, cianoalquilo, cicloalquilo, éster, ésteralquilo, haloalquilo, haloalcoxi, haloalquilcarbonilo, heteroarilo, heteroarilalquenilo, heteroarilalquilo, heleroarilsulfonilo, heterocicloalquenilo, heterocicloalquilo, heterocicloalquilalquilo, heterocicloalquilalcoxi, heterocicloalquilalquiltio, hidrogeno, hidroxialquilo y nulo, cualquiera de los cuales puede ser opcionalmente sustituido; y R8 es seleccionado de un grupo formado por alquilo inferior, cicloalquilo y heterocicloalquilo, cualquiera de los cuales puede ser opcionalmente sustituido; y con las siguientes condiciones: cuando X1 es nitrogeno, X2-X4 son C(R2), X5 es O o S y B es -NHC(O)NH-; A no puede ser fenil a menos que C sea fenil sustituido con -Oj(CH2)kX6, en el cual X6 es heterocicloalquilo; y donde B es -NHC(O)NH- y X5 es O entonces A no puede ser naftaleno.
ARP060105791A 2005-12-23 2006-12-26 PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. AR058403A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75399905P 2005-12-23 2005-12-23
US85173406P 2006-10-13 2006-10-13

Publications (1)

Publication Number Publication Date
AR058403A1 true AR058403A1 (es) 2008-01-30

Family

ID=37951807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105791A AR058403A1 (es) 2005-12-23 2006-12-26 PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF.

Country Status (4)

Country Link
US (1) US20070155764A1 (es)
AR (1) AR058403A1 (es)
TW (1) TW200804349A (es)
WO (1) WO2007076473A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942349A1 (en) 2004-12-23 2015-11-11 Deciphera Pharmaceuticals, LLC Enzyme modulators and treatments
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
CA2684666A1 (en) * 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
WO2009010871A2 (en) * 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as antagonists of adenosine a3 receptor
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
JP2011513329A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体
CN102149712A (zh) * 2008-02-29 2011-08-10 阵列生物制药公司 吡唑并[3，4-b]吡啶Raf抑制剂
WO2009111280A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
TW200940540A (en) * 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
NZ603654A (en) * 2008-10-29 2014-09-26 Deciphera Pharmaceuticals Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
US20120077851A1 (en) * 2009-06-09 2012-03-29 Medolution Limited Urea Derivatives as Kinase Inhibitors
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
AU2011248441A1 (en) * 2010-04-29 2012-12-20 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
WO2012021778A2 (en) * 2010-08-12 2012-02-16 The Regents Of The University Of California Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition
CN102406647A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 芳基脲衍生物用于制备治疗肾肿瘤药物的新用途
CN102406645A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 芳基脲衍生物用于制备治疗肾肿瘤药物的用途
CN102408408A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 具有抗肿瘤作用的芳基脲衍生物
CN102406646B (zh) * 2010-09-20 2015-09-09 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的用途
CN102406644A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的新用途
CN102432592A (zh) * 2010-09-29 2012-05-02 北大方正集团有限公司 具有抗肿瘤作用的芳基脲衍生物及其制备方法
JP2012102089A (ja) 2010-10-15 2012-05-31 Sumitomo Chemical Co Ltd ピリミジン化合物およびその有害生物防除用途
CN102558144A (zh) * 2010-12-22 2012-07-11 北大方正集团有限公司 一种芳基脲衍生物
CN102731413A (zh) * 2011-04-15 2012-10-17 上海医药工业研究院 一种脲类化合物、其制备方法、其中间体及其应用
TW201350479A (zh) * 2012-04-26 2013-12-16 Ono Pharmaceutical Co Ｔｒｋ阻害化合物
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
RU2667907C9 (ru) 2013-02-19 2019-01-31 Оно Фармасьютикал Ко., Лтд. ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ
AU2014369449B2 (en) * 2013-12-20 2018-07-05 Oxular Acquisitions Limited Urea derivatives useful as kinase inhibitors
CN104974132B (zh) * 2014-04-08 2017-05-17 北大方正集团有限公司 多取代的吡啶化合物、制备方法、用途及药物组合物
EP3191450B1 (en) * 2014-09-10 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA3098189A1 (en) * 2018-04-25 2020-02-13 Charles R. Drew University Of Medicine And Science Novel mct4 inhibitors and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
PE20221010A1 (es) 2019-08-14 2022-06-15 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
JP2022551668A (ja) 2019-10-11 2022-12-12 インサイト・コーポレイション Ｃｄｋ２阻害剤としての二環式アミン
CN115243681A (zh) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
KR20220123057A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 비정질 키나아제 억제제 제형 및 이의 사용 방법
CN113943281B (zh) * 2021-10-15 2023-08-15 深圳湾实验室 异恶唑嘧啶衍生物的合成方法及其应用
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI304061B (en) * 2000-10-20 2008-12-11 Eisai R&D Man Co Ltd Nitrogen-containing aromatic ring derivatives
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
JP4636486B2 (ja) * 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション 脈管形成阻害活性を有するアリール尿素
TW200406374A (en) * 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MXPA05009102A (es) * 2003-02-28 2006-05-31 Bayer Pharmaceuticals Corp Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos.
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
TW200529849A (en) * 2003-11-28 2005-09-16 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
EP1730111A2 (en) * 2004-01-30 2006-12-13 MERCK PATENT GmbH Substituted bisarylurea derivatives as kinase inhibitors
JPWO2005113550A1 (ja) * 2004-05-20 2008-03-27 三菱ウェルファーマ株式会社 アミノピリミジン誘導体及びその医薬としての用途

Also Published As

Publication number Publication date
TW200804349A (en) 2008-01-16
WO2007076473A3 (en) 2007-10-18
WO2007076473A2 (en) 2007-07-05
US20070155764A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
AR058403A1 (es) PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF.
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
AR092490A2 (es) Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
AR066460A2 (es) Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos
UY28150A1 (es) Agentes terapeuticos
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
SE0202133D0 (sv) Novel compounds
ECSP12007067A (es) Derivados de quinazolinona útiles como antagonistas vanilloides
TW200716528A (en) Cyclopropanecarboxamide derivatives
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
MX2007007098A (es) Derivados de pirrol que tienen actividad antagonista del receptor crth2.
EA201070169A1 (ru) 2,3-дигидробензо[1,4]диоксин-2-илметиловые производные в качестве альфа2с антагонистов для применения в лечении заболеваний перифирической центральной нервной системы
AR059961A1 (es) Compuesto derivado de fenil tetrahidro-indazol, composiciones farmaceuticas que lo comprenden, usos para preparar un medicamento para el tratamiento de una enfermedad mediada por una reduccion o desequilibrio en la funcion del receptor de glutamato y procesos para su preparacion
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
SE0303541D0 (sv) New compounds
EA201270266A1 (ru) Гетероциклические соединения
MX2009012383A (es) Derivados de arilamida pirimidona para el tratamiento de enfermedades neurodegenerativas.
ATE438617T1 (de) Substituierte cyclohexyl-1,4-diamin-derivate

Legal Events

Date Code Title Description
FB Suspension of granting procedure